Original Research
Published on 15 Apr 2025
YX-112, a novel celastrol-derived PROTAC, inhibits the development of triple-negative breast cancer by targeting the degradation of multiple proteins
in Experimental Pharmacology and Drug Discovery
- 1,107 views